menu
    • menu
    [{"orgOrder":0,"company":"Pulmonem","sponsor":"McGill University Health Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmonem \/ McGill University Health Centre","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ McGill University Health Centre"},{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MSIDS Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Not Applicable"},{"orgOrder":0,"company":"MUHC Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MUHC Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MUHC Foundation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MUHC Foundation \/ Not Applicable"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmonem \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Not Applicable"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dapsone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Pharma \/ SeegPharm"}]

    Find Clinical Drug Pipeline Developments & Deals for Dapsone

    Menu

    Dapsone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cosette Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Cosette Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : SeegPharm

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone 5%

                            Details : Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.

                            Brand Name : Aczone-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 13, 2023

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : SeegPharm

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pulmonem

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pulmonem

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promising COVID-19 Therapeutic Drug to start Phase 3 Clinical Trial in the United States

                            Details : PULM-001 data shown to prevent and treat acute respiratory distress syndrome due to SARS-CoV-2 infection and reduce mortality from 40% to 0% in a small, randomized clinical trial.

                            Brand Name : PULM-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 22, 2021

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MUHC Foundation

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            MUHC Foundation

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase III North American Clinical Trial for COVID-19 Treatment begins after FDA & Health Canada approval

                            Details : PULM-001 is a decades-old, safe and affordable oral antibacterial that also has well-recognized anti-inflammatory properties. It has been used to treat infectious diseases such as malaria, lupus, HIV and many other inflammatory infections.

                            Brand Name : PULM-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 14, 2021

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MSIDS Research Foundation

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            MSIDS Research Foundation

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MSIDS Research Foundation Study Finds That Leprosy Drugs Provide Potential Cure for Chronic Lyme Disease

                            Details : Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 28, 2020

                            Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pulmonem

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Pulmonem

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : McGill University Health Centre

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New COVID-19 Drug Therapy Developed by Canadian Biotech Start-up Headed for Phase III Clinical Trial Sponsored...

                            Details : The Phase III Clinical Trial is sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC) and will be conducted in seven centres in Canada and the United States as soon as the necessary funding has been secured.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 02, 2020

                            Lead Product(s) : Dapsone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : McGill University Health Centre

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth